AUPH News and Press, Aurinia Pharmaceuticals Inc From 12/09/19

Aurinia Pharmaceuticals (NASDAQ: AUPH ) prices public offering of 11.12M common shares at $15/share for gross proceeds of $166.7M. More news on: Aurinia Pharmaceuticals Inc., Healthcare stocks news, Read more ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the pricing of its underwritten public offering of 11,115,16...

Aurinia Pharmaceuticals (NASDAQ: AUPH ) commences an $150M public offering of common shares. Underwriters' over-allotment will be an additional $22.5M of stock. More news on: Aurinia Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, Read more ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that it has commenced a registered underwritten public offer...

Aurinia Pharmaceuticals ( AUPH ) announced that it had achieved the primary endpoint for its phase 3 study using its drug voclosporin along with background therapy to treat patients with Lupus Nephritis ((LN)). Not only did the biotech meet on the primary endpoint of the study with stati...

Thursday brought some uncertainty to Wall Street, as major benchmarks traded on both sides of the unchanged mark at various points during the session. Initial optimism about possible progress on the trade front with U.S.-Chinese negotiations gave way to a more somber assessment of the proceeding...

Gainers: Aurinia Pharmaceuticals (NASDAQ: AUPH ) +95% . More news on: Aurinia Pharmaceuticals Inc., Duluth Holdings Inc., Atreca, Inc., Stocks on the move, Read more ...

Aurinia Pharmaceuticals (NASDAQ: AUPH ) +102%  as voclosporin successful in late-stage lupus nephritis study. More news on: Aurinia Pharmaceuticals Inc., ACADIA Pharmaceuticals Inc., SeaChange International, Inc., Stocks on the move, Read more ...

Aurinia Pharmaceuticals (NASDAQ: AUPH) , a late-stage developmental biotech, saw its shares rocket higher in after-hours trading Wednesday by a whopping 125%. The biotech's shares took flight in response to positive late-stage trial results for the experimental lupus nephritis drug candidate ...

A 357-subject Phase 3 clinical trial evaluating Aurinia Pharmaceuticals' (NASDAQ: AUPH ) lead drug voclosporin, combined with mycophenolate and low-dose corticosteroids, in lupus nephritis patients met the primary and key secondary endpoints. More news on: Aurinia Pharmaceuticals Inc.,...